Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

167 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The impact of capsaicin intake on risk of developing gastric cancers: a meta-analysis.
Pabalan N, Jarjanazi H, Ozcelik H. Pabalan N, et al. J Gastrointest Cancer. 2014 Sep;45(3):334-41. doi: 10.1007/s12029-014-9610-2. J Gastrointest Cancer. 2014. PMID: 24756832
The homogeneous (P(heterogeneity) = 0.27-0.37) H. pylori (OR 0.60 and 1.69) effects were highly significant (P < 0.001) in the low and medium-high intake analyses, respectively. ...
The homogeneous (P(heterogeneity) = 0.27-0.37) H. pylori (OR 0.60 and 1.69) effects were highly significant (P < 0.001) in the low …
A meta-analysis of the C1420T polymorphism in cytosolic serine hydroxymethyltransferase (SHMT1) among Caucasian colorectal cancer populations.
Pabalan N, Jarjanazi H, Ozcelik H. Pabalan N, et al. Int J Colorectal Dis. 2013 Jul;28(7):925-32. doi: 10.1007/s00384-013-1639-3. Epub 2013 Jan 16. Int J Colorectal Dis. 2013. PMID: 23322534
Association between BRIP1 (BACH1) polymorphisms and breast cancer risk: a meta-analysis.
Pabalan N, Jarjanazi H, Ozcelik H. Pabalan N, et al. Breast Cancer Res Treat. 2013 Jan;137(2):553-8. doi: 10.1007/s10549-012-2364-2. Epub 2012 Dec 6. Breast Cancer Res Treat. 2013. PMID: 23225146
Menopausal status modifies breast cancer risk associated with the myeloperoxidase (MPO) G463A polymorphism in Caucasian women: a meta-analysis.
Pabalan N, Jarjanazi H, Sung L, Li H, Ozcelik H. Pabalan N, et al. PLoS One. 2012;7(3):e32389. doi: 10.1371/journal.pone.0032389. Epub 2012 Mar 9. PLoS One. 2012. PMID: 22427832 Free PMC article.
Meta-analysis of two ERCC2 (XPD) polymorphisms, Asp312Asn and Lys751Gln, in breast cancer.
Pabalan N, Francisco-Pabalan O, Sung L, Jarjanazi H, Ozcelik H. Pabalan N, et al. Breast Cancer Res Treat. 2010 Nov;124(2):531-41. doi: 10.1007/s10549-010-0863-6. Epub 2010 Apr 9. Breast Cancer Res Treat. 2010. PMID: 20379847
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.
Ding YC, McGuffog L, Healey S, Friedman E, Laitman Y, Paluch-Shimon S, Kaufman B; SWE-BRCA, Liljegren A, Lindblom A, Olsson H, Kristoffersson U, Stenmark-Askmalm M, Melin B, Domchek SM, Nathanson KL, Rebbeck TR, Jakubowska A, Lubinski J, Jaworska K, Durda K, Gronwald J, Huzarski T, Cybulski C, Byrski T, Osorio A, Cajal TR, Stavropoulou AV, Benítez J, Hamann U; HEBON, Rookus M, Aalfs CM, de Lange JL, Meijers-Heijboer HE, Oosterwijk JC, van Asperen CJ, Gómez García EB, Hoogerbrugge N, Jager A, van der Luijt RB; EMBRACE, Easton DF, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Lalloo F, Izatt L, Eeles R, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, Godwin AK, Pathak H; GEMO Study Collaborators, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Barjhoux L, Léoné M, Gauthier-Villars M, Caux-Moncoutier V, de Pauw A, Hardouin A, Berthet P, Dreyfus H, Ferrer SF, Collonge-Rame MA, Sokolowska J, Buys S, Daly M, Miron A, Terry MB, Chung W, John EM, Southey M, Goldgar D, Singer CF, Tea MK, Gschwantler-Kaulich D, Fink-Retter A, Hansen TV, Ejlertsen B, Johannsson OT, Offit K, Sarrel K, Gaudet MM, Vijai J, Robson M, Piedmonte MR, Andrews L, Cohn D, DeMars LR, DiSilvestro P, Rodriguez G, Toland AE, Montagna M, Agata S, Imyanitov E, Isaacs C, Janavicius R, Lazaro C, Blanco I, Ramus SJ, Sucheston L, Karlan BY, Gross J, Ganz PA, Beattie MS, Schmutzler RK, Wappenschmidt B, Meindl A, Arnold N, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Nevanlinna H, Aittomäki K, Simard J; KConFab Investigators, Spurdle AB, Beesley J, Chen X, Tomlinson GE, Weitzel J, Garber JE, Olopade OI, Rubinstein WS, Tung N, Blum JL, Narod SA, Brummel S, Gillen DL, Lindor N, Fredericksen Z, Pankratz VS, Couch FJ, Radice P, Peterlongo P, Greene MH, Loud JT, Mai PL, Andrulis IL, Glendon G, Ozcelik H; OCGN, Gerdes AM, Thomassen M, Jensen UB, Skytte AB, Caligo MA, Lee A, Chenevix-Trench G, Antoniou AC, Neuhausen SL; Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Ding YC, et al. Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1362-70. doi: 10.1158/1055-9965.EPI-12-0229. Epub 2012 Jun 22. Cancer Epidemiol Biomarkers Prev. 2012. PMID: 22729394 Free PMC article. Clinical Trial.
p53 missense but not truncation mutations are associated with low levels of p21(CIP1/WAF1) mRNA expression in primary human sarcomas.
Mousses S, Gokgoz N, Wunder JS, Ozcelik H, Bull S, Bell RS, Andrulis IL. Mousses S, et al. Br J Cancer. 2001 Jun 15;84(12):1635-9. doi: 10.1054/bjoc.2001.1844. Br J Cancer. 2001. PMID: 11401317 Free PMC article.
HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry.
Quenneville LA, Phillips KA, Ozcelik H, Parkes RK, Knight JA, Goodwin PJ, Andrulis IL, O'Malley FP. Quenneville LA, et al. Cancer. 2002 Nov 15;95(10):2068-75. doi: 10.1002/cncr.10949. Cancer. 2002. PMID: 12412159
167 results
Jump to page
Feedback